

University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln

US Army Research

U.S. Department of Defense

2013

Novel 16S rRNA Methyltransferase RmtH Produced by *Klebsiella pneumoniae* Associated with War-Related Trauma

Jessica A. O'Hara

University of Pittsburgh - Main Campus

Patrick McGann

Walter Reed Army Institute of Research

Erik C. Snesrud

Walter Reed Army Institute of Research

Robert J. Clifford

Walter Reed Army Institute of Research

Paige E. Waterman

Walter Reed Army Institute of Research

See next page for additional authors

Follow this and additional works at: <https://digitalcommons.unl.edu/usarmyresearch>

O'Hara, Jessica A.; McGann, Patrick; Snesrud, Erik C.; Clifford, Robert J.; Waterman, Paige E.; Lesho, Emil P.; and Doi, Yohei, "Novel 16S rRNA Methyltransferase RmtH Produced by *Klebsiella pneumoniae* Associated with War-Related Trauma" (2013). *US Army Research*. 256.

<https://digitalcommons.unl.edu/usarmyresearch/256>

This Article is brought to you for free and open access by the U.S. Department of Defense at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in US Army Research by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors

Jessica A. O'Hara, Patrick McGann, Erik C. Snesrud, Robert J. Clifford, Paige E. Waterman, Emil P. Lesho, and Yohei Doi

Novel 16S rRNA Methyltransferase RmtH Produced by *Klebsiella pneumoniae* Associated with War-Related Trauma

Jessica A. O'Hara,^a Patrick McGann,^b Erik C. Snestrud,^b Robert J. Clifford,^b Paige E. Waterman,^b Emil P. Lesho,^b Yohei Doi^a

Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA^a; Multidrug-resistant Organism Repository and Surveillance Network (MRSN), Walter Reed Army Institute of Research, Silver Spring, Maryland, USA^b

***Klebsiella pneumoniae* strain MRSN2404 was isolated from the chronic wound of a soldier who had been wounded in Iraq in 2006. The strain displayed very high MICs of all aminoglycosides, including arbekacin. A gene encoding a novel 16S rRNA methyltransferase, now designated RmtH, was identified. RmtH had 64% identity with RmtB1 and RmtB2. *rmtH* was bracketed by two copies of ISCR2, which may have played a role in its mobilization.**

Aminoglycosides, along with β -lactams and fluoroquinolones, remain one of the key classes of antimicrobial agents in the treatment of infections caused by Gram-negative bacteria. Mechanisms of resistance to aminoglycosides include enzymatic modification of the drugs, modification of the aminoglycoside-binding site, decreased permeability across the bacterial outer membranes, and augmented efflux. Among them, production of acquired 16S rRNA methyltransferase (16S RMTase) is the most worrisome since it compromises the activity of all aminoglycosides (1). Since the initial reports in 2003, nine such enzymes have been identified (1, 2, 18). With the exception of NpmA, which methylates residue A1408 of the 16S rRNA, they methylate residue G1405 and confer high-level resistance to all aminoglycosides formulated for intravenous use, including gentamicin, tobramycin, amikacin, and arbekacin. Among the G1405 16S RMTases, ArmA and RmtB appear to be the most widely distributed worldwide,

TABLE 1 MICs of aminoglycosides

Strain	MIC (μ g/ml)		
	Gentamicin	Tobramycin	Amikacin
<i>K. pneumoniae</i> MRSN2404	>256	>256	>256
<i>E. coli</i> DH10B(pKp2404K1)	>256	>256	>256
<i>E. coli</i> DH10B(prmtHBX7)	>256	>256	>256
<i>E. coli</i> DH10B(pBC-SK(-))	0.25	0.5	1

having been found in multiple species of the *Enterobacteriaceae*, as well as *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. Production of 16S RMTases is frequently accompanied by coproduction of a carbapenemase or extended-spectrum β -lactamase (ESBL), which further facilitates multidrug resistance. In the United States, the most commonly encountered 16S RMTase is ArmA, produced by multidrug-resistant (MDR) and extensively drug-resistant (XDR) *A. baumannii*, whereas the presence of RmtB and RmtE has been reported for rare strains of *Escherichia coli*.

In this article, we describe identification of RmtH, a novel 16S RMTase, in a clinical strain of *Klebsiella pneumoniae*. *K. pneumoniae* MRSN2404 was recovered from a 28-year-old male soldier who had suffered a tibial fracture from an explosion in Iraq in 2006. The strain was collected by the Multidrug-resistant Organism Repository and Surveillance Network (MRSN) to enhance infection prevention, inform empirical therapy, and influence policy (3). Following evacuation to the United States, a culture from the intramedullary wound of the right tibia grew XDR *A. baumannii*, ESBL-producing *K. pneumoniae*, and vancomycin-resistant enterococci. Subsequently, the patient had chronic draining wounds associated with the blast injury that occasionally expressed shrapnel. *K. pneumoniae* MRSN2404 was then isolated from the wound in 2009. This strain was found to have very high




FIG 1 Phylogenetic tree of G1405 16S RMTases. The tree was generated using the tools available at <http://www.phylogeny.fr> (17). GenBank references are as follows: ArmA, AY220558; RmtA, AB120321; RmtB1, AB103506; RmtB2, JN968578; RmtC, AB194779; RmtD1, DQ914960; RmtD2, HQ401565; RmtE, GU201947; RmtF, JQ808129; RmtG, JX486113.

Received 6 February 2013 Returned for modification 23 February 2013

Accepted 3 March 2013

Published ahead of print 11 March 2013

Address correspondence to Yohei Doi, yod4@pitt.edu.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AAC.00266-13

```

ArmA ----MDKNDVVKKILESKKYENLSDIVEKVVSISEKKYK-LKEVENYSKKKHLHQIWS 54
RmtA ----MSFDDALASILSSKKYRSLCPD'TVRRILDQEWGRHKS PKLAVEATR'RLHGICGA 55
RmtB1 ----MNINDALTSILASKKYRALCPD'TVRRILTEEWGRHKS PKQ'VEAAR'RLHGICGA 55
RmtB2 ----MNINDALTSILASKKYRALCPD'TVRRILTEEWGRHKS PKQ'AVEAAR'RLHGICGA 55
RmtC MKTNDNYIEEVTAKVLTSGKYSTLYPP'TVRRVTERLFD'RY-PKQLEKEVRK'KLHQAYGA 59
RmtD1 ----MSELKEKLLASKKYR'DVCPD'TIERIWRECSAKFKKEKD'VKAAREALHGVTGA 53
RmtD2 ----MSELKEKLLASKKYR'DVCPD'TIERIWRECSAKFKKEKD'ADKAAREALHGVTGA 53
RmtE ----MNIDEMVAEVLSSKKYTSVDP'PAVVRVCMETAPKYPKKKEA'IKAVKNELHIHEV 55
RmtF ---MDERAQAALDALLSAKNLR'DVCPETVRRVFMELLP'RYRKP'KDAEKAAR'HLHQITGA 57
RmtG ----MRDPLFEKLAASKKYR'DVCPD'TIARILTECR'AKYRREKEIDKAAREALHGITAA 54
RmtH ----MTIEQAADILSSKKYQLLCPD'TVVRILTQEWGRHKKPKQ'AVERTRE'RLHGICGA 55

ArmA YYSAYPNWDKLLKKYNQGG-----LSIEDLLKIHSS'NTERVA--TLN 94
RmtA YVTPES-LKAAAAALSVG-----DVQKALSLHAST'KERLA--ELD 92
RmtB1 YVTPES-LKAAAAALSAG-----DVKKALSLHAST'KERLA--ELD 92
RmtB2 YVTPES-LKAAAAALSAG-----DVKKALSLHAST'KERLA--ELD 92
RmtC YIGGID-GKRLEKKIEKIIHEI'PNPTTDEATRTEWEKEIC'IKILNLHTST'NERTV--AYD 116
RmtD1 FMTERE-YKRAMEMAAAR-----DWEAL'LGMHASTRERL'PVESMD 92
RmtD2 FMTERE-YKRAMELAATR-----DWEAL'LGMHASTRERL'PVESMD 92
RmtE FLQNEC-YKNALSFLSQLS'LD'FNN-----AQ'LIDITMQ'IMQSHST'KERLG--DIE 103
RmtF FMTADA-QKKARALLAR'WNEGDE-----SALA'AAALSLHASTRERL'P--GAD 100
RmtG FMTDAE-YRRAMEIAVRGG-----ELAE'LMECHASTRERL'PLEETD 94
RmtH YLAPQV-EKQASTALAAG-----DVQKALALHAST'RERLD--TYP 92

ArmA DFYTYVFGNIKHVSSILD'FGCGFNPLALYQWN-ENEKIIYHAYD'IDRAEIAFLSS'IGKL 153
RmtA CLYDFIFSG-GVPHRVL'DIACGLNPLALFI----RDIT'SVWACD'IHQGLGDVIT'PF'FAHQ 147
RmtB1 TLYDFIFSA-ET'PRRVL'DIACGLNPLALYE----RG'IASVWGC'DIHQGLGDVIT'PF'FAREK 147
RmtB2 TLYDFIFSA-ET'PRRVL'DIACGLNPLALYE----RG'VASVWGC'DVHQGLGDVIT'PF'FAREK 147
RmtC ELYQKIFEVTGVPTSITD'AGCALNPF'F'F'F'FTEAGML'GQYIGFDL'DKGMIEAIEHSLR'ITL 176
RmtD1 RVFDQLFEASGTPARIL'DLACGLNPVYLAHR---LP'NAAT'GVDI'ISGQCVNVI----RAF 145
RmtD2 RVFDQLFEAIGTPARIL'DLACGLNPVYLAHR---LP'NAALAGV'DISGQCVNVI----RAF 145
RmtE AVC'SFLSTHISKEG'SVMDIGCGFN'PFALPLL--HE'FPAT'YAYD'ICSEGINILN'KYFSIL 161
RmtF EWMRRVSPFLGADARVLD'LACGLNPIL'LSG---MGV'TNALGMD'IHLCVRLVNETARAR 156
RmtG AVYARLLGAPDESA--LDL'ACGLNPAYLQNR---Y'PEMRV'TGDI'ISGQCVRVL----RAL 145
RmtH QLYQFVFEN-NL'PARVLD'IAACGLNPLMLHR---Q'GVASVWGC'DIHQGLGNVLT'PYAQKH 147

ArmA KTT--IKYRFLNKESD--VYKGYD'VVFLLKML'PVLKQQ'DVN--ILD'FLQLFHTQ'NFVVSF 208
RmtA GLD--FTFALQ'DVMCTP--PTET'GD'LALVFKL'PLL'EREQAGAAMALLQALAT'PRIAVSF 203
RmtB1 DWD--FTFALQ'DVLCAP--PAEAGD'LALIFKLL'PLL'EREQAGSAMALLQSLNTPRMAVSF 203
RmtB2 DWD--FTFALQ'DVLCAP--PAET'GD'LALIFKLL'PLL'EREQAGSAMALLQSLNTPRMAVSF 203
RmtC NAPEGI'VVKQGDILSD---PSGE'SDLLMFKLYT'LDRQ'EASGLKILQEWKYKNAV'ISF 233
RmtD1 GG---AEARLGDLLCE--IPEDE'ANAALLFKV'LPLLERQ'RAGAAMDALMRVNAE'WIVASF 200
RmtD2 GG---AEARLGDLLCE--IPEDE'ADAALMFKV'LPLLERQ'TGAAMEALMRVNAE'WIVASF 200
RmtE KKGE-YRAELLD'AVSVT--PKEK'VDVALLFKL'LPL'QQKKG'RGFS'ILEELDFDKA'IVSF 218
RmtF GWH--TRARACD'LLSE--I'PAEE'ADAALLMKL'L'PVLEAQKT'GRAAE'LLASLRAPRLV'VTF 212
RmtG G---VDARLGD'LLAENAI'PRARYS'VALLFKL'L'PLDRQ'SAGAARRI'LEAVNADAL'ICSF 201
RmtH GWD--FTFALHDVLCAP--VAASGDMALVFKL'PLL'EREQ'PGALALALR'LDAPVICVSF 203

ArmA PIKSLSGKEKGM'EENYQLWFES'FTK-GWIKILD'SKVIGNELVYIT'SGFQK----- 257
RmtA PTRSLGGRGKGM'EANYSAW'FEGALP-DEFE'IEDTKTIG'IELVYMIKRNK----- 251
RmtB1 PTRSLGGRGKGM'EANYAAW'FEGGLP-AEFE'IEDKKTIG'TELIYLIKNG----- 251
RmtB2 PTRSLGGRGKGM'EANYAAW'FEGGLP-TEFE'IEDKKTIG'TELIYLIKNG----- 251
RmtC PIKTI'SGRDVGMEENYTVK'FENDLVGSDLR'IMQK'LKLG'NEMFYIVSRL----- 281
RmtD1 PTRSLGGRNVGMEKHYS'EWEAHVP-ENRAI'AAARLT'GENELFYV'LKRK----- 247
RmtD2 PTRSLGGRNVGMEKHYS'EWEAHVP-ENRAI'AAARLT'GENELFYV'LKRK----- 247
RmtE PIKSLGGKQKGM'ETFYSNL'FEENLP--SSLE'IEKQ'TFSNEMFYI'QNKT'KNGGNQS---- 273
RmtF PTRTLGGRGVM'EKHYADW'FERILP-DT'LSVDR'RFV'SDELVYLV'ERT----- 259
RmtG PTRSLSGRNVGM'AVHYAAW'RDQLP-EKWR'IERTVETD'NELYV'LKEKQDGEAVR'GGDSH 260
RmtH PTRSLGGRGKGM'HQHYATW'FEGLVA-PHFTVQ'HHTLI'GDELLYRIQ'PNPA----- 252

ArmA ----
RmtA ----
RmtB1 ----
RmtB2 ----
RmtC ----
RmtD1 ----
RmtD2 ----
RmtE ----
RmtF ----
RmtG RESE 264
RmtH ----

```

FIG 2 Amino acid sequence alignment of G1405 16S RMTases. The alignment was generated using the ClustalW software program (www.ebi.ac.uk/Tools/msa/clustalw2/).

MICs (>256 µg/ml) of all aminoglycosides tested, including gentamicin, tobramycin, amikacin, and arbekacin, when tested by the standard broth microdilution method recommended by the Clinical and Laboratory Standards Institute (4). It was also resistant to ceftriaxone, ceftazidime, cefepime, aztreonam, and ciprofloxacin but remained susceptible to ertapenem and imipenem. The strain was phenotypically confirmed as an ESBL producer, and screening of β-lactamase genes with PCR and sequencing showed that it carried *bla*_{CTX-M-15} as well as *bla*_{SHV-1} and *bla*_{OXA-1}. Multilocus sequence typing (www.pasteur.fr/mlst) (5) assigned the strain to sequence type (ST) 48, an ST which has been reported in association with ESBL production worldwide (6–10).

Given the resistance phenotype consistent with 16S RMTase production, the strain was screened for 16S RMTase genes using PCR (2, 11, 12). However, PCR was negative for all known 16S RMTase genes. We therefore proceeded with further experiments to identify the determinant of high-level aminoglycoside resistance. The genomic DNA of *K. pneumoniae* MRSN2404 was extracted, digested with KpnI (New England BioLabs, Ipswich, MA), and ligated with the vector pBC-SK(–) (Agilent Technologies, Santa Clara, CA), which had been digested with the same enzyme. Electrocompetent *Escherichia coli* DH10B was transformed with this genomic library, and transformants were selected on tryptic soy agar (TSA) plates containing chloramphenicol (30 µg/ml) and gentamicin (50 µg/ml). This procedure yielded a single colony, which was cross-resistant to other aminoglycosides as well. The recombinant plasmid harbored by this transformant (pKp2404K1) was then fully sequenced. The sequencing revealed the presence of a 3.1-kb insert, which contained an open reading frame (ORF) corresponding to a 252-amino-acid sequence. This ORF showed 64% amino acid identity with the 16S RMTases RmtB1 and RmtB2 and 63% identity with RmtA. Identity with other 16S RMTases was much lower, ranging from 25% with ArmA to 39% with RmtD1, RmtD2, and RmtF (Fig. 1). The ORF was designated *rmtH* according to the proposed nomenclature of acquired 16S RMTases (13). We then performed PCR cloning of *rmtH* using the primers *rmtH*-XbaI-fwd (5'-CGCTCTAGAATG ACCATTGAACAGGCAGC-3') and *rmtG*-BamHI-rev (5'-CGC GGATCCTCAAGCTGGGTTTGGCTGGA-3') (the restriction sites are underlined). The PCR product was digested with XbaI and BamHI and ligated with pBC-SK(–) digested with the same enzymes. Transformants were obtained using the method above. A transformant harboring a recombinant plasmid with the intact *rmtH* structural gene (prmtHBX7), as confirmed by sequencing, was used for susceptibility testing. Susceptibility testing was performed using Etest (bioMérieux, Hazelwood, MO) according to the manufacturer's instructions. As shown in Table 1, the original genomic clone, as well as the PCR clone, showed high-level resistance to gentamicin, tobramycin, and amikacin, as expected. Based on the pattern of aminoglycoside resistance and the amino acid alignment with known 16S RMTases, RmtH likely functioned as a G1405 16S RMTase (Fig. 2).

The full sequence of pKp2404K1 revealed that *rmtH* was bracketed by two copies of ISCR2 in tandem. ISCR2 is an IS91-like transposable element which is found in association with various resistance genes, including those for sulfonamide, trimethoprim, and florfenicol (14), and also tetracycline and cephalosporin (15, 16). It is believed to facilitate mobilization of the genetic elements downstream. To our knowledge, this is the first instance where a 16S RMTase gene was found in association with ISCR2. ISCR2 is

usually found intact upstream of a resistance gene, while the second copy downstream is typically truncated (14). Since ISCR2 possesses a KpnI restriction site, we were not able to assess whether the two copies of ISCR2 were intact or not. Nonetheless, this unique arrangement suggested that they likely played a role in the initial mobilization of *rmtH* to *K. pneumoniae* MRSN2404.

Attempts to mobilize *rmtH* to *E. coli* by either transformation or conjugation were not successful. DNA hybridization of S1 nuclease-treated genomic DNA separated by pulsed-field gel electrophoresis (PFGE) with an *rmtH*-specific probe did not yield any band despite the presence of multiple plasmids on the PFGE gel. Finally, the *rmtH* probe hybridized to an approximately 500-kb band which was generated by PFGE following XbaI digestion (data not shown). These findings suggested that *rmtH* was likely located on the chromosome.

In summary, we report a novel 16S RMTase, RmtH, identified in an ESBL-producing *K. pneumoniae* strain which was recovered from a soldier who had been wounded during an operation in Iraq. The finding underscores the diversity of 16S RMTases and highlights the importance of continued surveillance in identifying emerging antimicrobial resistance mechanisms.

Nucleotide sequence accession number. The nucleotide sequence reported in this study has been submitted to the GenBank under accession number [KC544262](https://www.ncbi.nlm.nih.gov/nuccore/KC544262).

ACKNOWLEDGMENTS

We gratefully acknowledge the assistance of Michael Zapor in strain collection.

Major funding for the MRSN is provided by the U.S. Army Medical Command, the Defense Medical Research and Development Program, and the Department of Defense Global Emerging Infections Surveillance and Response System (GEIS). Y.D. is supported in part through the Research Scholar Development Award funded by the National Institute of Allergy and Infectious Diseases (K22AI080584).

This material has been reviewed by the Walter Reed Army Institute of Research. There was no objection to its presentation. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of the Army or the Department of Defense.

REFERENCES

- Wachino J, Arakawa Y. 2012. Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: an update. *Drug Resist. Updat.* 15:133–148.
- Galimand M, Courvalin P, Lambert T. 2012. RmtF, a new member of the aminoglycoside resistance 16S rRNA N7 G1405 methyltransferase family. *Antimicrob. Agents Chemother.* 56:3960–3962.
- Waterman P, Kwak Y, Clifford R, Julius M, Onmus-Leone F, Tsurgeon C, Riley M, Black C, McGann P, Lesho E. 2012. A multidrug-resistance surveillance network: 1 year on. *Lancet Infect. Dis.* 12:587–588.
- Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
- Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. 2005. Multilocus sequence typing of *Klebsiella pneumoniae* nosocomial isolates. *J. Clin. Microbiol.* 43:4178–4182.
- Marcade G, Brisse S, Bialek S, Marcon E, Leflon-Guibout V, Passet V, Moreau R, Nicolas-Chanoine MH. 2012. The emergence of multidrug-resistant *Klebsiella pneumoniae* of international clones ST13, ST16, ST35, ST48 and ST101 in a teaching hospital in the Paris region. *Epidemiol. Infect.* 2012:1–8. doi:10.1017/S0950268812002099.
- Ma L, Lu PL, Siu LK, Hsieh MH. 2013. Molecular typing and resistance mechanisms of imipenem-non-susceptible *Klebsiella pneumoniae* in Taiwan: results from the Taiwan surveillance of antibiotic resistance (TSAR) study, 2002–2009. *J. Med. Microbiol.* 62:101–107.

8. Ko KS, Lee JY, Baek JY, Suh JY, Lee MY, Choi JY, Yeom JS, Kim YS, Jung SI, Shin SY, Heo ST, Kwon KT, Son JS, Kim SW, Chang HH, Ki HK, Chung DR, Peck KR, Song JH. 2010. Predominance of an ST11 extended-spectrum β -lactamase-producing *Klebsiella pneumoniae* clone causing bacteraemia and urinary tract infections in Korea. *J. Med. Microbiol.* 59:822–828.
9. Elhani D, Bakir L, Aouni M, Passet V, Arlet G, Brisse S, Weill FX. 2010. Molecular epidemiology of extended-spectrum β -lactamase-producing *Klebsiella pneumoniae* strains in a university hospital in Tunis, Tunisia, 1999–2005. *Clin. Microbiol. Infect.* 16:157–164.
10. An S, Chen J, Wang Z, Wang X, Yan X, Li J, Chen Y, Wang Q, Xu X, Li J, Yang J, Wang H, Gao Z. 2012. Predominant characteristics of CTX-M-producing *Klebsiella pneumoniae* isolates from patients with lower respiratory tract infection in multiple medical centers in China. *FEMS Microbiol. Lett.* 332:137–145.
11. Doi Y, Arakawa Y. 2007. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. *Clin. Infect. Dis.* 45: 88–94.
12. Davis MA, Baker KN, Orfe LH, Shah DH, Besser TE, Call DR. 2010. Discovery of a gene conferring multiple-aminoglycoside resistance in *Escherichia coli*. *Antimicrob. Agents Chemother.* 54:2666–2669.
13. Doi Y, Wachino J, Arakawa Y. 2008. Nomenclature of plasmid-mediated 16S rRNA methylases responsible for panaminoglycoside resistance. *Antimicrob. Agents Chemother.* 52:2287–2288.
14. Toleman MA, Bennett PM, Walsh TR. 2006. ISCR elements: novel gene-capturing systems of the 21st century? *Microbiol. Mol. Biol. Rev.* 70:296–316.
15. Poirel L, Mugnier PD, Toleman MA, Walsh TR, Rapoport MJ, Petroni A, Nordmann P. 2009. ISCR2, another vehicle for *bla*_{VEB} gene acquisition. *Antimicrob. Agents Chemother.* 53:4940–4943.
16. Seputiene V, Povilonis J, Suziedeliene E. 2012. Novel variants of AbaR resistance islands with a common backbone in *Acinetobacter baumannii* isolates of European clone II. *Antimicrob. Agents Chemother.* 56:1969–1973.
17. Dereeper A, Guignon V, Blanc G, Audic S, Buffet S, Chevenet F, Dufayard JF, Guindon S, Lefort V, Lescot M, Claverie JM, Gascuel O. 2008. Phylogeny.fr: robust phylogenetic analysis for the non-specialist. *Nucleic Acids Res.* 36:W465–W469.
18. Bueno MFC, Francisco GR, O'Hara JA, de Oliveira Garcia D, Doi Y. 2013. Coproduction of 16S rRNA methyltransferase RmtD and RmtG with KPC-2 and CTX-M group extended-spectrum β -lactamases in *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* 57:2397–2400.